Skip to main content
TipRanks
Go Ultimate75% OFF

Acutaas Chemicals (ACUTAAS) AI Stock Analysis

6 Followers
IN:ACUTAAS

Acutaas Chemicals

(NSE:ACUTAAS)

Select Model
Rating:74Outperform
Price Target:INR 4,459.00â–²(10.29% Upside)
Action:reiterated
Date:10/30/26

Strong profitability, revenue growth, balance-sheet quality, and technical momentum drive the score. The primary constraints are persistently negative free cash flow and an elevated P/E ratio.

Positive Factors
Revenue and Profitability GrowthThe sharp FY2026 acceleration in revenue and profitability indicates stronger earnings capacity and potential operating leverage. If maintained, this improvement can support reinvestment, strengthen the company’s competitive position, and provide a larger base for future growth over the next several quarters.
Negative Factors
Persistently Negative Free Cash FlowNegative free cash flow across the reported period means accounting profits have not translated into surplus cash after investment or working-capital needs. If persistent, this can constrain internally funded expansion, increase reliance on financing, and reduce flexibility during weaker operating periods.

Acutaas Chemicals (ACUTAAS) vs. iShares MSCI India ETF (INDA)

-25%0%25%50%75%100%125%150%IN:ACUTAAS+136.30%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 330.69B
Dividend Yield
0.06%
Average Volume (3M)
36.34K
Price to Earnings (P/E)
75.6
Beta (1Y)
0.99
Revenue Growth
45.18%
EPS Growth
96.07%
Country
India
Employees
1,007
Sector
General
Sector Strength
55
Industry
Chemicals - Specialty

Acutaas Chemicals Business Overview & Revenue Model

Company Description

Based in Surat, India, Acutaas Chemicals Limited, founded in 2004, is engaged in the development, production, and global distribution of pharmaceutical intermediates. These crucial compounds are utilized in both regulated and generic active pharmaceu...

Acutaas Chemicals Financial Statement Overview

Summary

Strong profitability and revenue growth, improving returns, and minimal leverage support the score. However, persistently negative free cash flow and capital intensity are material weaknesses.

Income Statement

88Very Positive

Balance Sheet

82Very Positive

Cash Flow

52Neutral
Financial statement breakdown
BreakdownTTMMar 2025Mar 2023Mar 2022Mar 2021Mar 2020
Income Statement
Total Revenue10.97B13.39B7.17B5.18B3.41B2.40B
Gross Profit5.17B6.20B2.63B1.94B1.22B776.58M
EBITDA3.02B4.80B1.04B1.08B811.14M438.14M
Net Income2.24B3.56B427.73M719.46M539.99M274.70M
Balance Sheet
Total Assets16.96B19.84B10.96B6.59B4.13B2.32B
Cash, Cash Equivalents and Short-Term Investments2.41B2.25B533.12M615.46M26.85M38.22M
Total Debt83.49M355.96M2.17B8.44M1.37B594.20M
Total Liabilities2.57B2.73B4.13B1.37B2.46B1.20B
Stockholders Equity14.14B16.54B6.74B5.22B1.67B1.12B
Cash Flow
Free Cash Flow-46.49M-285.38M-1.56B-424.18M-794.33M54.71M
Operating Cash Flow1.37B2.99B1.25B-86.60M271.45M270.77M
Investing Cash Flow-1.40B-2.74B-3.68B-1.24B-1.00B-239.44M
Financing Cash Flow-91.38M53.74M2.39B1.40B721.08M1.94M

Acutaas Chemicals Technical Analysis

Technical Analysis SentimentPositive
Last Price4042.95

Price Trends

50DMA3399.01Positive
100DMA3378.02Positive
200DMA2914.98Positive

Market Momentum

MACD186.35Negative
RSI68.82Neutral
STOCH71.96Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ACUTAAS, the sentiment is Positive. The current price of 4042.95 is above the 20-day moving average (MA) of 3645.16, above the 50-day MA of 3399.01, and above the 200-day MA of 2914.98, indicating a bullish trend. The MACD of 186.35 indicates Negative momentum. The RSI at 68.82 is Neutral, neither overbought nor oversold. The STOCH value of 71.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ACUTAAS.

Acutaas Chemicals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:ACUTAAS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:ACUTAASIN:ACUTAAS74OutperformINR 331.00B75.60―0.06%45.18%96.07%
IN:VINATIORGAIN:VINATIORGA73OutperformINR 115.82B28.36―0.76%10.98%-5.48%
IN:AETHERIN:AETHER71OutperformINR 222.43B89.38――30.76%28.12%
IN:ATULIN:ATUL68NeutralINR 152.11B19.71―0.58%18.15%42.38%
IN:ANURASIN:ANURAS63NeutralINR 148.26B71.44―0.11%23.80%16.11%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:AARTIINDIN:AARTIIND47NeutralINR 174.79B29.53―0.21%39.85%103.71%

* General Sector Average

Performance Comparison

0%50%100%IN:ACUTAASIN:AARTIINDIN:AETHERIN:ANURASIN:ATULIN:VINATIORGADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ACUTAAS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ACUTAASAcutaas Chemicals Ltd4042.952333.83136.55%
IN:AARTIINDAARTI Industries Ltd481.8587.4822.18%
IN:AETHERAether Industries Ltd.1675.75828.3097.74%
IN:ANURASAnupam Rasayan India Ltd.1302.25218.1820.13%
IN:ATULAtul Limited5166.40-819.40-13.69%
IN:VINATIORGAVinati Organics Limited1117.25-548.76-32.94%

Acutaas Chemicals Corporate Events

Acutaas Chemicals Publishes Q2 and Half-Year 2026 Investor Presentation

Oct 27, 2026

Acutaas Chemicals Limited has released an investor presentation detailing its financial results for the second quarter and half year ended September 30, 2026, along with updates on other business matters. The presentation, published in compliance wit...

Acutaas Chemicals Sets Record Date for 50% Final Dividend

Aug 29, 2026

Acutaas Chemicals Limited has set 17 September 2026 as the record date to determine shareholders eligible to receive a proposed final dividend for the financial year 2025-26. The company plans a payout of Rs. 2.50 per fully paid equity share of face...

Acutaas Chemicals Outlines TDS Rules on Proposed FY26 Final Dividend

Aug 29, 2026

Acutaas Chemicals has informed shareholders that its board has recommended a final dividend of Rs 2.50 per equity share with a face value of Re 5 for FY 2025-26, subject to approval at the 19th Annual General Meeting on 24 September 2026. The dividen...

Acutaas opens South Korean semiconductor materials plant via Indichem

Aug 28, 2026

Acutaas Chemicals has inaugurated a semiconductor materials plant in Gongju, South Korea, via its step-down subsidiary Indichem Inc., completing the state-of-the-art facility just eleven months after groundbreaking. The plant sits on a 16,513.7 sq. m...

Acutaas Chemicals Publishes AGM Notice to Meet SEBI Disclosure Rules

Aug 24, 2026

Acutaas Chemicals Limited has notified exchanges that it has published newspaper advertisements regarding its 19th Annual General Meeting, scheduled for September 24, 2026 at 11:30 a.m. IST. The notices appeared in the Financial Express All India Eng...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026